Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australia switches chloramphenicol eye drops

This article was originally published in The Tan Sheet

Executive Summary

Australia moves chloramphenicol-containing eye drops to nonprescription distribution by pharmacists, harmonizing the country's regulation with New Zealand's. The National Drugs and Poisons Schedule Committee in October said that other nonprescription products are indicated for mild cases of bacterial conjunctivitis, but it is "sensible to allow pharmacists to supply cholramphenicol for the treatment of more severe, uncomplicated cases." Australia and New Zealand are harmonizing requirements for therapeutic products and establishing a joint regulatory scheme under the Trans-Tasman Mutual Recognition Arrangement (1"The Tan Sheet" Feb. 2, 2009). Chloramphenicol-containing eye drops remain Rx in the U.S

You may also be interested in...



Therapeutic Product Regulatory Reforms Considered Down Under

Australia's Therapeutic Goods Association plans to implement a number of regulations to update and streamline the existing framework for over-the-counter and prescription drugs as well as medical devices

QUOTED. 3 March 2021. Greg Dadika.

Medtech Insight spoke to attorney Greg Dadika about mass tort litigation, including industry trends, how to find the right law firm, and when it’s the right time to settle a suit. See what Dadika, an attorney at the law firm Greenberg Traurig LLP, said about it here.

Sotagliflozin Hail Mary? Lexicon Seeks Opportunity For Formal Hearing On FDA Intent To Deny Approval

After complete response letter, Lexicon triggers rarely used mechanism for formal hearing, prompting US FDA to publicly list its problems with the proposed type 1 diabetes drug, for which Sanofi had originally sought approval.

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel